01.11.2022 11:43:04
|
IDEXX Laboratories Inc Profit Climbs In Q3, Beats estimates
(RTTNews) - IDEXX Laboratories Inc (IDXX) announced earnings for its third quarter that increased from last year and beat the Street estimates.
The company's earnings came in at $180.94 million, or $2.15 per share. This compares with $175.24 million, or $2.03 per share, in last year's third quarter.
Analysts on average had expected the company to earn $2.04 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 3.9% to $841.66 million from $810.42 million last year.
IDEXX Laboratories Inc earnings at a glance (GAAP) :
-Earnings (Q3): $180.94 Mln. vs. $175.24 Mln. last year. -EPS (Q3): $2.15 vs. $2.03 last year. -Analyst Estimate: $2.04 -Revenue (Q3): $841.66 Mln vs. $810.42 Mln last year.
-Guidance: Full year EPS guidance: $7.74 - $7.98
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu IDEXX Laboratoriesmehr Nachrichten
03.02.25 |
Schwacher Wochentag in New York: NASDAQ Composite beendet den Handel im Minus (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 zum Ende des Montagshandels schwächer (finanzen.at) | |
03.02.25 |
Verluste in New York: NASDAQ Composite nachmittags in Rot (finanzen.at) | |
03.02.25 |
Schwacher Handel in New York: NASDAQ 100 am Montagnachmittag schwächer (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
03.02.25 |
Zurückhaltung in New York: NASDAQ Composite mittags in Rot (finanzen.at) |
Analysen zu IDEXX Laboratoriesmehr Analysen
Aktien in diesem Artikel
IDEXX Laboratories | 444,20 | -1,53% |
|